University of Saskatchewan
Acute intermittent hypoxia (AIH) as a non-invasive therapy for the treatment of multiple sclerosis (MS)
Abstract
dc:description.abstractMultiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) marked by immune-mediated demyelination and neurodegeneration. Remyelination and the prevention of neurodegeneration play crucial roles in mitigating disability in MS, especially in progressive forms of disease when the capacity for repair is diminished. Previously, our research demonstrated that acute intermittent hypoxia (AIH) could enhance repair in CNS demyelination in the MOG35-55 experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Female EAE mice that reached near peak EAE disease were administered either AIH (2 hrs – 10 cycles of 5 min 11% oxygen followed by 5 min 21% oxygen) or Normoxia (control; 2 hrs continuous 21% oxygen) treatment daily for 7 days. AIH induced an elevated level of beneficial adaptive stress that improved all indices of repair examined. Significant improvements in daily clinical scores and functional recovery were observed as well as positive effects on remyelination, axon protection, and the recruitment of oligodendrocyte precursor cells to damaged and demyelinated areas of lumbar spinal cord. Further, AIH led to a significant 80% reduction in inflammation within the CNS with the remaining microglia/macrophages polarized toward a pro-repair state. This supported that AIH has the potential to enhance intrinsic repair mechanisms in the CNS and MS. This thesis aims to expand the understanding of the impacts of AIH as a potential therapy for MS as well as provide insight into potential mechanisms by which AIH exerts its effects. I hypothesized that “AIH treatment promotes CNS repair and alters disease progression in the MOG35-55 EAE mouse model of MS, with similar outcomes in both sexes. Further, AIH treatment will modulate early and regeneration-associated genes and restore blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB) integrity”. In summary, the findings suggest that AIH holds promise as a novel, non-invasive therapy that is capable of enhancing CNS repair and remyelination long-term in both sexes and potentially exerts its effects through early gene responses and through restoring BBB and BSCB integrity. This approach may serve as a promising neuroreparative strategy for MS.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy (Ph.D.)
- Level thesis:degree_level
- Doctoral
- Discipline thesis:degree_discipline
- Anatomy, Physiology, and Pharmacology
- Department thesis:degree_department
- Anatomy, Physiology, and Pharmacology
- Grantor
- University of Saskatchewan
- Year dc:date.issued
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Tokarska, Nataliya
- Advisors dc:contributor.advisor
-
- Verge, Valerie M.K
- Donkers, Sarah J
- Committee members dc:contributor.committeemember
-
- Knox, Katherine B
- Levin, Michael C
- Krishnan, Anand
- Popescu, Bogdan F
- Campanucci, Veronica A
- Karimi-Abdolrezaee, Soheila
- ORCID person:identifier.orcid
Subjects
dc:subject × 8Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/10388/16675